Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 50 entries
Sorted by: Best Match Show Resources per page
Thoracic surgery in India: challenges and opportunities.

Journal of thoracic disease

Yendamuri S.
PMID: 27651933
J Thorac Dis. 2016 Aug;8:S596-600. doi: 10.21037/jtd.2016.05.08.

India has the dubitable honor of being ranked first in the world with regards to lung disease burden. A good proportion of this disease burden is amenable to surgical treatment. However, patients have limited access to quality thoracic surgical...

Cite
Yendamuri S. Thoracic surgery in India: challenges and opportunities. J Thorac Dis. 2016;8:S596-600doi: 10.21037/jtd.2016.05.08.
Yendamuri, S. (2016). Thoracic surgery in India: challenges and opportunities. Journal of thoracic disease, 8S596-600. https://doi.org/10.21037/jtd.2016.05.08
Yendamuri, Sai. "Thoracic surgery in India: challenges and opportunities." Journal of thoracic disease vol. 8 (2016): S596-600. doi: https://doi.org/10.21037/jtd.2016.05.08
Yendamuri S. Thoracic surgery in India: challenges and opportunities. J Thorac Dis. 2016 Aug;8:S596-600. doi: 10.21037/jtd.2016.05.08. PMID: 27651933; PMCID: PMC5009067.
Copy Download .nbib Format: NLM
Imaging Axonal Degeneration and Repair in Preclinical Animal Models of Multiple Sclerosis.

Frontiers in immunology

Yandamuri SS, Lane TE.
PMID: 27242796
Front Immunol. 2016 May 19;7:189. doi: 10.3389/fimmu.2016.00189. eCollection 2016.

Multiple sclerosis (MS) is a central nervous system (CNS) disease characterized by chronic neuroinflammation, demyelination, and axonal damage. Infiltration of activated lymphocytes and myeloid cells are thought to be primarily responsible for white matter damage and axonopathy. Over time,...

Cite
Yandamuri SS, Lane TE. Imaging Axonal Degeneration and Repair in Preclinical Animal Models of Multiple Sclerosis. Front Immunol. 2016;7:189doi: 10.3389/fimmu.2016.00189.
Yandamuri, S. S., & Lane, T. E. (2016). Imaging Axonal Degeneration and Repair in Preclinical Animal Models of Multiple Sclerosis. Frontiers in immunology, 7189. https://doi.org/10.3389/fimmu.2016.00189
Yandamuri, Soumya S, and Lane, Thomas E. "Imaging Axonal Degeneration and Repair in Preclinical Animal Models of Multiple Sclerosis." Frontiers in immunology vol. 7 (2016): 189. doi: https://doi.org/10.3389/fimmu.2016.00189
Yandamuri SS, Lane TE. Imaging Axonal Degeneration and Repair in Preclinical Animal Models of Multiple Sclerosis. Front Immunol. 2016 May 19;7:189. doi: 10.3389/fimmu.2016.00189. eCollection 2016. PMID: 27242796; PMCID: PMC4871863.
Copy Download .nbib Format: NLM
Advances in lung cancer surgery.

Journal of carcinogenesis

Hennon MW, Yendamuri S.
PMID: 23346014
J Carcinog. 2012;11:21. doi: 10.4103/1477-3163.105341. Epub 2012 Dec 31.

The last few years have witnessed an explosion of the use of minimally invasive techniques for the detection, diagnosis, and treatment of all stages of lung Cancer. The use of these techniques has improved the risk-benefit ratio of surgery...

Cite
Hennon MW, Yendamuri S. Advances in lung cancer surgery. J Carcinog. 2012;11:21doi: 10.4103/1477-3163.105341.
Hennon, M. W., & Yendamuri, S. (2012). Advances in lung cancer surgery. Journal of carcinogenesis, 1121. https://doi.org/10.4103/1477-3163.105341
Hennon, Mark W, and Yendamuri, Sai. "Advances in lung cancer surgery." Journal of carcinogenesis vol. 11 (2012): 21. doi: https://doi.org/10.4103/1477-3163.105341
Hennon MW, Yendamuri S. Advances in lung cancer surgery. J Carcinog. 2012;11:21. doi: 10.4103/1477-3163.105341. Epub 2012 Dec 31. PMID: 23346014; PMCID: PMC3548435.
Copy Download .nbib Format: NLM
Treatment of non-small cell lung cancer ≤2 cm in size: less may not be more.

Annals of translational medicine

Horan SM, Yendamuri S.
PMID: 28149865
Ann Transl Med. 2016 Dec;4(24):503. doi: 10.21037/atm.2016.12.59.

No abstract available.

Cite
Horan SM, Yendamuri S. Treatment of non-small cell lung cancer ≤2 cm in size: less may not be more. Ann Transl Med. 2016;4(24):503doi: 10.21037/atm.2016.12.59.
Horan, S. M., & Yendamuri, S. (2016). Treatment of non-small cell lung cancer ≤2 cm in size: less may not be more. Annals of translational medicine, 4(24), 503. https://doi.org/10.21037/atm.2016.12.59
Horan, Siobain M, and Yendamuri, Sai. "Treatment of non-small cell lung cancer ≤2 cm in size: less may not be more." Annals of translational medicine vol. 4,24 (2016): 503. doi: https://doi.org/10.21037/atm.2016.12.59
Horan SM, Yendamuri S. Treatment of non-small cell lung cancer ≤2 cm in size: less may not be more. Ann Transl Med. 2016 Dec;4(24):503. doi: 10.21037/atm.2016.12.59. PMID: 28149865; PMCID: PMC5233475.
Copy Download .nbib Format: NLM
The microbiome and lung cancer.

Journal of thoracic disease

Maddi A, Sabharwal A, Violante T, Manuballa S, Genco R, Patnaik S, Yendamuri S.
PMID: 30863606
J Thorac Dis. 2019 Jan;11(1):280-291. doi: 10.21037/jtd.2018.12.88.

It has become increasingly clear that we live in a symbiotic relationship with microbes within us. We are just beginning to unravel the nature and strength of this relationship and its impact on both physiology and by extension, pathology....

Cite
Maddi A, Sabharwal A, Violante T, et al. The microbiome and lung cancer. J Thorac Dis. 2019;11(1):280-291doi: 10.21037/jtd.2018.12.88.
Maddi, A., Sabharwal, A., Violante, T., Manuballa, S., Genco, R., Patnaik, S., & Yendamuri, S. (2019). The microbiome and lung cancer. Journal of thoracic disease, 11(1), 280-291. https://doi.org/10.21037/jtd.2018.12.88
Maddi, Abhiram, et al. "The microbiome and lung cancer." Journal of thoracic disease vol. 11,1 (2019): 280-291. doi: https://doi.org/10.21037/jtd.2018.12.88
Maddi A, Sabharwal A, Violante T, Manuballa S, Genco R, Patnaik S, Yendamuri S. The microbiome and lung cancer. J Thorac Dis. 2019 Jan;11(1):280-291. doi: 10.21037/jtd.2018.12.88. PMID: 30863606; PMCID: PMC6384374.
Copy Download .nbib Format: NLM
Anatomical considerations in bronchoscopy.

Journal of thoracic disease

Ryan B, Yendamuri K, Yendamuri S.
PMID: 29214069
J Thorac Dis. 2017 Sep;9:S1123-S1127. doi: 10.21037/jtd.2017.08.116.

A thorough understanding of intrathoracic anatomy enables the interventional bronchoscopist to perform procedures efficaciously. The review of the anatomy of the thoracic cavity focuses first on the trachea and the relationship of the airway with surrounding structures, knowledge important...

Cite
Ryan B, Yendamuri K, Yendamuri S. Anatomical considerations in bronchoscopy. J Thorac Dis. 2017;9:S1123-S1127doi: 10.21037/jtd.2017.08.116.
Ryan, B., Yendamuri, K., & Yendamuri, S. (2017). Anatomical considerations in bronchoscopy. Journal of thoracic disease, 9S1123-S1127. https://doi.org/10.21037/jtd.2017.08.116
Ryan, Brienne, et al. "Anatomical considerations in bronchoscopy." Journal of thoracic disease vol. 9 (2017): S1123-S1127. doi: https://doi.org/10.21037/jtd.2017.08.116
Ryan B, Yendamuri K, Yendamuri S. Anatomical considerations in bronchoscopy. J Thorac Dis. 2017 Sep;9:S1123-S1127. doi: 10.21037/jtd.2017.08.116. PMID: 29214069; PMCID: PMC5696545.
Copy Download .nbib Format: NLM
Comparative evaluation of the bond strength of self-adhering and bulk-fill flowable composites to MTA Plus, Dycal, Biodentine, and TheraCal: an .

Restorative dentistry & endodontics

Raina A, Sawhny A, Paul S, Nandamuri S.
PMID: 32110539
Restor Dent Endod. 2020 Jan 08;45(1):e10. doi: 10.5395/rde.2020.45.e10. eCollection 2020 Feb.

OBJECTIVES: This study aimed to compare the shear bond strength (SBS) of a self-adhering flowable composite (Dyad Flow) and a bulk-fill flowable composite (Smart Dentin Replacement [SDR]) to several pulp-capping materials, including MTA Plus, Dycal, Biodentine, and TheraCal.MATERIALS AND...

Cite
Raina A, Sawhny A, Paul S, et al. Comparative evaluation of the bond strength of self-adhering and bulk-fill flowable composites to MTA Plus, Dycal, Biodentine, and TheraCal: an . Restor Dent Endod. 2020;45(1):e10doi: 10.5395/rde.2020.45.e10.
Raina, A., Sawhny, A., Paul, S., & Nandamuri, S. (2020). Comparative evaluation of the bond strength of self-adhering and bulk-fill flowable composites to MTA Plus, Dycal, Biodentine, and TheraCal: an . Restorative dentistry & endodontics, 45(1), e10. https://doi.org/10.5395/rde.2020.45.e10
Raina, Aakrati, et al. "Comparative evaluation of the bond strength of self-adhering and bulk-fill flowable composites to MTA Plus, Dycal, Biodentine, and TheraCal: an ." Restorative dentistry & endodontics vol. 45,1 (2020): e10. doi: https://doi.org/10.5395/rde.2020.45.e10
Raina A, Sawhny A, Paul S, Nandamuri S. Comparative evaluation of the bond strength of self-adhering and bulk-fill flowable composites to MTA Plus, Dycal, Biodentine, and TheraCal: an . Restor Dent Endod. 2020 Jan 08;45(1):e10. doi: 10.5395/rde.2020.45.e10. eCollection 2020 Feb. PMID: 32110539; PMCID: PMC7030959.
Copy Download .nbib Format: NLM
Impact of a Thoracic Multidisciplinary Conference on Lung Cancer Outcomes.

The Annals of thoracic surgery

Gaudioso C, Sykes A, Whalen PE, Attwood KM, Masika MM, Demmy TL, Dexter EU, Hennon MW, Picone AL, Yendamuri SS, Nwogu CE.
PMID: 33744217
Ann Thorac Surg. 2021 Mar 18; doi: 10.1016/j.athoracsur.2021.03.017. Epub 2021 Mar 18.

BACKGROUND: With the complexity of cancer treatment rising, the role of multidisciplinary conferences (MDCs) in making diagnostic and treatment decisions has become critical. This study evaluated the impact of a thoracic MDC (T-MDC) on lung cancer care quality and...

Cite
Gaudioso C, Sykes A, Whalen PE, et al. Impact of a Thoracic Multidisciplinary Conference on Lung Cancer Outcomes. Ann Thorac Surg. 2021;doi: 10.1016/j.athoracsur.2021.03.017.
Gaudioso, C., Sykes, A., Whalen, P. E., Attwood, K. M., Masika, M. M., Demmy, T. L., Dexter, E. U., Hennon, M. W., Picone, A. L., Yendamuri, S. S., & Nwogu, C. E. (2021). Impact of a Thoracic Multidisciplinary Conference on Lung Cancer Outcomes. The Annals of thoracic surgery, . https://doi.org/10.1016/j.athoracsur.2021.03.017
Gaudioso, Carmelo, et al. "Impact of a Thoracic Multidisciplinary Conference on Lung Cancer Outcomes." The Annals of thoracic surgery vol. (2021). doi: https://doi.org/10.1016/j.athoracsur.2021.03.017
Gaudioso C, Sykes A, Whalen PE, Attwood KM, Masika MM, Demmy TL, Dexter EU, Hennon MW, Picone AL, Yendamuri SS, Nwogu CE. Impact of a Thoracic Multidisciplinary Conference on Lung Cancer Outcomes. Ann Thorac Surg. 2021 Mar 18; doi: 10.1016/j.athoracsur.2021.03.017. Epub 2021 Mar 18. PMID: 33744217.
Copy Download .nbib Format: NLM
Association of BMI With Benefit of Metformin Plus Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients With Advanced Lung Adenocarcinoma: A Secondary Analysis of a Phase 2 Randomized Clinical Trial.

JAMA oncology

Arrieta O, Zatarain-Barrón ZL, Turcott JG, Barrón F, Yendamuri S, Cardona AF, Rosell R.
PMID: 35024769
JAMA Oncol. 2022 Jan 13; doi: 10.1001/jamaoncol.2021.7015. Epub 2022 Jan 13.

No abstract available.

Cite
Arrieta O, Zatarain-Barrón ZL, Turcott JG, et al. Association of BMI With Benefit of Metformin Plus Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients With Advanced Lung Adenocarcinoma: A Secondary Analysis of a Phase 2 Randomized Clinical Trial. JAMA Oncol. 2022;doi: 10.1001/jamaoncol.2021.7015.
Arrieta, O., Zatarain-Barrón, Z. L., Turcott, J. G., Barrón, F., Yendamuri, S., Cardona, A. F., & Rosell, R. (2022). Association of BMI With Benefit of Metformin Plus Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients With Advanced Lung Adenocarcinoma: A Secondary Analysis of a Phase 2 Randomized Clinical Trial. JAMA oncology, . https://doi.org/10.1001/jamaoncol.2021.7015
Arrieta, Oscar, et al. "Association of BMI With Benefit of Metformin Plus Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients With Advanced Lung Adenocarcinoma: A Secondary Analysis of a Phase 2 Randomized Clinical Trial." JAMA oncology vol. (2022). doi: https://doi.org/10.1001/jamaoncol.2021.7015
Arrieta O, Zatarain-Barrón ZL, Turcott JG, Barrón F, Yendamuri S, Cardona AF, Rosell R. Association of BMI With Benefit of Metformin Plus Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients With Advanced Lung Adenocarcinoma: A Secondary Analysis of a Phase 2 Randomized Clinical Trial. JAMA Oncol. 2022 Jan 13; doi: 10.1001/jamaoncol.2021.7015. Epub 2022 Jan 13. PMID: 35024769.
Copy Download .nbib Format: NLM
Obesity-Specific Association of Statin Use and Reduced Risk of Recurrence of Early Stage NSCLC.

JTO clinical and research reports

Patnaik SK, Petrucci C, Barbi J, Seager RJ, Pabla S, Yendamuri S.
PMID: 34877556
JTO Clin Res Rep. 2021 Nov 09;2(12):100254. doi: 10.1016/j.jtocrr.2021.100254. eCollection 2021 Dec.

INTRODUCTION: Statins, used for their lipid-lowering activity, have anti-inflammatory and anticancer properties as well. We evaluated this potential benefit of statin use in patients with NSCLC.METHODS: All 613 patients with pathologic stage 1 or 2 NSCLC who had lobectomy...

Cite
Patnaik SK, Petrucci C, Barbi J, et al. Obesity-Specific Association of Statin Use and Reduced Risk of Recurrence of Early Stage NSCLC. JTO Clin Res Rep. 2021;2(12):100254doi: 10.1016/j.jtocrr.2021.100254.
Patnaik, S. K., Petrucci, C., Barbi, J., Seager, R. J., Pabla, S., & Yendamuri, S. (2021). Obesity-Specific Association of Statin Use and Reduced Risk of Recurrence of Early Stage NSCLC. JTO clinical and research reports, 2(12), 100254. https://doi.org/10.1016/j.jtocrr.2021.100254
Patnaik, Santosh K, et al. "Obesity-Specific Association of Statin Use and Reduced Risk of Recurrence of Early Stage NSCLC." JTO clinical and research reports vol. 2,12 (2021): 100254. doi: https://doi.org/10.1016/j.jtocrr.2021.100254
Patnaik SK, Petrucci C, Barbi J, Seager RJ, Pabla S, Yendamuri S. Obesity-Specific Association of Statin Use and Reduced Risk of Recurrence of Early Stage NSCLC. JTO Clin Res Rep. 2021 Nov 09;2(12):100254. doi: 10.1016/j.jtocrr.2021.100254. eCollection 2021 Dec. PMID: 34877556; PMCID: PMC8633682.
Copy Download .nbib Format: NLM
Rare airway tumors: an update on current diagnostic and management strategies.

Journal of thoracic disease

Saoud M, Patil M, Dhillon SS, Pokharel S, Picone A, Hennon M, Yendamuri S, Harris K.
PMID: 27621844
J Thorac Dis. 2016 Aug;8(8):1922-34. doi: 10.21037/jtd.2016.07.40.

No abstract available.

Cite
Saoud M, Patil M, Dhillon SS, et al. Rare airway tumors: an update on current diagnostic and management strategies. J Thorac Dis. 2016;8(8):1922-34doi: 10.21037/jtd.2016.07.40.
Saoud, M., Patil, M., Dhillon, S. S., Pokharel, S., Picone, A., Hennon, M., Yendamuri, S., & Harris, K. (2016). Rare airway tumors: an update on current diagnostic and management strategies. Journal of thoracic disease, 8(8), 1922-34. https://doi.org/10.21037/jtd.2016.07.40
Saoud, Marwan, et al. "Rare airway tumors: an update on current diagnostic and management strategies." Journal of thoracic disease vol. 8,8 (2016): 1922-34. doi: https://doi.org/10.21037/jtd.2016.07.40
Saoud M, Patil M, Dhillon SS, Pokharel S, Picone A, Hennon M, Yendamuri S, Harris K. Rare airway tumors: an update on current diagnostic and management strategies. J Thorac Dis. 2016 Aug;8(8):1922-34. doi: 10.21037/jtd.2016.07.40. PMID: 27621844; PMCID: PMC4999752.
Copy Download .nbib Format: NLM
Sarcopenia is a predictor of outcomes after lobectomy.

Journal of thoracic disease

Miller JA, Harris K, Roche C, Dhillon S, Battoo A, Demmy T, Nwogu CE, Dexter EU, Hennon M, Picone A, Attwood K, Yendamuri S.
PMID: 29600075
J Thorac Dis. 2018 Jan;10(1):432-440. doi: 10.21037/jtd.2017.12.39.

BACKGROUND: As screening for lung cancer rises, an increase in the diagnosis of early stage lung cancers is expected. Lobectomy remains the standard treatment, but there are alternatives, consideration of which requires an estimation of the risk of surgery....

Cite
Miller JA, Harris K, Roche C, et al. Sarcopenia is a predictor of outcomes after lobectomy. J Thorac Dis. 2018;10(1):432-440doi: 10.21037/jtd.2017.12.39.
Miller, J. A., Harris, K., Roche, C., Dhillon, S., Battoo, A., Demmy, T., Nwogu, C. E., Dexter, E. U., Hennon, M., Picone, A., Attwood, K., & Yendamuri, S. (2018). Sarcopenia is a predictor of outcomes after lobectomy. Journal of thoracic disease, 10(1), 432-440. https://doi.org/10.21037/jtd.2017.12.39
Miller, James A, et al. "Sarcopenia is a predictor of outcomes after lobectomy." Journal of thoracic disease vol. 10,1 (2018): 432-440. doi: https://doi.org/10.21037/jtd.2017.12.39
Miller JA, Harris K, Roche C, Dhillon S, Battoo A, Demmy T, Nwogu CE, Dexter EU, Hennon M, Picone A, Attwood K, Yendamuri S. Sarcopenia is a predictor of outcomes after lobectomy. J Thorac Dis. 2018 Jan;10(1):432-440. doi: 10.21037/jtd.2017.12.39. PMID: 29600075; PMCID: PMC5863199.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 50 entries